CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
BioPharma Dive
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
pharminent
May 6, 2026 (Last updated: May 6, 2026)
BioPharma Dive
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
